Effects of cabozantinib: A Synthesis of Findings from 15 Studies

  1. Home
  2. Effects of cabozantinib
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of cabozantinib: A Synthesis of Findings from 15 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of cabozantinib: A Synthesis of Findings from 15 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Cabozantinib is a multi-targeted tyrosine kinase inhibitor used in the treatment of various cancers, including renal cell cancer, medullary thyroid cancer, and hepatocellular carcinoma. 10 , 2 , 5 , 6 Cabozantinib inhibits various tyrosine kinases, such as vascular endothelial growth factor receptor 2 (VEGFR2), c-MET, and RET, and suppresses tumor growth and angiogenesis. 13 , 4 , 8 Cabozantinib is not only used as a single agent but is also considered promising in combination with immunotherapy. 10 , 3 , 14 Cabozantinib may enhance the effectiveness of immunotherapy by activating immune cells and reducing immunosuppression in the tumor microenvironment. 14 , 4 Additionally, cabozantinib may influence bone metabolism and could be used for the treatment of bone metastases. 7 Cabozantinib is also expected to have a protective effect against damage to the kidneys caused by high blood sugar. 2

Benefits and Risks

Benefit Summary

Cabozantinib is a multi-targeted tyrosine kinase inhibitor used in the treatment of various cancers. 10 , 2 , 5 , 6 Cabozantinib has an effect on suppressing tumor growth and angiogenesis. 13 , 4 , 8 Cabozantinib is not only used as a single agent but is also considered promising in combination with immunotherapy. 10 , 3 , 14 Cabozantinib may enhance the effectiveness of immunotherapy by activating immune cells and reducing immunosuppression in the tumor microenvironment. 14 , 4 Additionally, cabozantinib may influence bone metabolism and could be used for the treatment of bone metastases. 7 Cabozantinib is also expected to have a protective effect against damage to the kidneys caused by high blood sugar. 2

Risk Summary

Cabozantinib can cause various side effects. 13 , 6 , 15 These include hypertension, diarrhea, fatigue, nausea, loss of appetite, rash, liver dysfunction, and QT interval prolongation. 11 , 9 Cabozantinib should not be used in pregnant or breastfeeding women. 13 Cabozantinib may interact with other medications. 13 Consult a doctor before using cabozantinib and be aware of the side effects.

Comparison between Studies

Similarities among Studies

Many studies have shown that cabozantinib is effective in treating cancer. 10 , 2 , 5 , 6 Cabozantinib has the effect of suppressing tumor growth and angiogenesis. 13 , 4 , 8 Cabozantinib is not only used as a single agent but is also considered promising in combination with immunotherapy. 10 , 3 , 14 Cabozantinib may enhance the effectiveness of immunotherapy by activating immune cells and reducing immunosuppression in the tumor microenvironment. 14 , 4

Differences among Studies

The effects of cabozantinib vary depending on the type and stage of cancer. 10 , 2 , 5 , 6 Cabozantinib can also cause a variety of side effects. 13 , 6 , 15 The severity of side effects varies from patient to patient. 13 , 6 , 15 Consult a doctor before using cabozantinib and be aware of the side effects.

Consistency and Discrepancies in Results

Cabozantinib has been shown to be effective in treating various cancers. 10 , 2 , 5 , 6 However, cabozantinib can cause various side effects. 13 , 6 , 15 The severity of side effects varies from patient to patient. 13 , 6 , 15 Consult a doctor before using cabozantinib and be aware of the side effects.

Notes on Applying the Results to Real Life

Cabozantinib is a multi-targeted tyrosine kinase inhibitor used in the treatment of various cancers. 10 , 2 , 5 , 6 Cabozantinib has an effect on suppressing tumor growth and angiogenesis. 13 , 4 , 8 Cabozantinib is not only used as a single agent but is also considered promising in combination with immunotherapy. 10 , 3 , 14 Cabozantinib may enhance the effectiveness of immunotherapy by activating immune cells and reducing immunosuppression in the tumor microenvironment. 14 , 4 Additionally, cabozantinib may influence bone metabolism and could be used for the treatment of bone metastases. 7 Cabozantinib is also expected to have a protective effect against damage to the kidneys caused by high blood sugar. 2 Consult a doctor before using cabozantinib and be aware of the side effects.

Limitations of Current Research

Long-term effects of cabozantinib have not been sufficiently studied yet. 13 , 6 , 15 Further research is also needed on how cabozantinib affects various cancer types and stages. 10 , 2 , 5 , 6

Future Research Directions

Research on the long-term effects and side effects of cabozantinib is needed. 13 , 6 , 15 Further research is also needed on how cabozantinib affects various cancer types and stages. 10 , 2 , 5 , 6

Conclusion

Cabozantinib has been shown to be effective in treating various cancers. 10 , 2 , 5 , 6 Cabozantinib has an effect on suppressing tumor growth and angiogenesis. 13 , 4 , 8 Cabozantinib is not only used as a single agent but is also considered promising in combination with immunotherapy. 10 , 3 , 14 Cabozantinib may enhance the effectiveness of immunotherapy by activating immune cells and reducing immunosuppression in the tumor microenvironment. 14 , 4 Additionally, cabozantinib may influence bone metabolism and could be used for the treatment of bone metastases. 7 Cabozantinib is also expected to have a protective effect against damage to the kidneys caused by high blood sugar. 2 Consult a doctor before using cabozantinib and be aware of the side effects.

Literature analysis of 15 papers
Positive Content
14
Neutral Content
1
Negative Content
0
Article Type
1
0
0
2
15
3.

Exploring the synergistic effects of cabozantinib and a programmed cell death protein 1 inhibitor in metastatic renal cell carcinoma with machine learning.

Author: DuránIgnacio, CastellanoDaniel, PuenteJavier, Martín-CouceLidia, BelloEsther, AnidoUrbano, MasJosé Manuel, CostaLuis

mccRCC treatment

This study suggests that the combination of cabozantinib with a PD1 inhibitor may be synergistic in the treatment of metastatic clear cell renal cell carcinoma (mccRCC). Cabozantinib may enhance the effects of PD1 inhibitors on immunosurveillance by modulating the immune system, while PD1 inhibitors may boost the antiangiogenic and pro-apoptotic effects of cabozantinib.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

4.

Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib.

Author: ScirocchiFabio, NapoletanoChiara, PaceAngelica, Rahimi KoshkakiHassan, Di FilippoAlessandra, ZizzariIlaria Grazia, NutiMarianna, RughettiAurelia

Immunostimulation
Prostate cancer treatment

Cabozantinib is a multitarget tyrosine kinase inhibitor used to treat medullary thyroid cancer, metastatic renal cell carcinoma, and hepatocellular carcinoma. This study found that Cabozantinib may exert an immunostimulatory role in prostate cancer by inducing immunogenic stress of prostate cancer cells and directly modulating dendritic cells (DCs).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

5.

Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence.

Author: SantoniMatteo, IacovelliRoberto, ColonnaValentina, KlinzStephan, MauriGiorgio, NutiMarianna

Cancer treatment

This article discusses the role of altered receptor tyrosine kinase (RTK) signaling in tumorigenesis and the use of cabozantinib, an oral tyrosine kinase inhibitor, in the treatment of patients with progressive metastatic medullary thyroid cancer, advanced renal cell carcinoma, and hepatocellular carcinoma.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

6.

Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model.

Author: CarraSilvia, GaudenziGermano, DicitoreAlessandra, SaronniDavide, CantoneMaria Celeste, PlebaniAlice, GhilardiAnna, BorghiMaria Orietta, HoflandLeo J, PersaniLuca, VitaleGiovanni

MTC treatment

Vandetabib (VAN) and cabozantinib (CAB) showed comparable antiproliferative effects in medullary thyroid carcinoma (MTC), but CAB exhibited more potent anti-angiogenic activity than VAN. Both drugs inhibited angiogenesis in a dose-dependent manner, suggesting that CAB might be more relevant for the treatment of MTC.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

7.

Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinoma.

Author: RattaRaffaele, VerzoniElena, MennittoAlessia, PantanoFrancesco, MartinettiAntonia, RaimondiAlessandra, SepePierangela, SottotettiElisa, MennittoRoberta, MorelliDaniele, SantiniDaniele, de BraudFilippo G, ProcopioGiuseppe

Improved bone health
Reduced bone resorption
Transient PTH increase

Cabozantinib significantly reduced bone resorption and showed a transient secondary increase of parathyroid hormone (PTH) in patients with metastatic renal cell carcinoma (mRCC).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

8.

Transcription Factor SOX18 Promotes Clear Cell Renal Cell Carcinoma Progression and Alleviates Cabozantinib-Mediated Inhibitory Effects.

Author: HuaqiYin, CaipengQin, QiangWang, YiqingDu, XiangDai, XuTang, XiaoweiZhang, QingLi, ShijunLiu, TaoXu

ccRCC treatment target

SOX18 is a transcription factor that promotes clear cell renal cell carcinoma (ccRCC) carcinogenesis and metastasis. This study found that elevated SOX18 expression was associated with advanced pathologic grades and poor patient survival.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

9.

Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension.

Author: MillingRikke Vilsbøll, GrimmDaniela, KrügerMarcus, GrosseJirka, KoppSascha, BauerJohann, InfangerManfred, WehlandMarkus

Increased PFS
MTC treatment
Prolonged lifetime
Cardiovascular disease
Hypertension

Tyrosine kinase inhibitors (TKIs) are effective in treating medullary thyroid cancer (MTC) and have shown promising results in increasing progression-free survival, but they are associated with hypertension, which can worsen patient well-being.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

11.

Assessment of cabozantinib treatment on QT interval in a phase 3 study in medullary thyroid cancer: evaluation of indirect QT effects mediated through treatment-induced changes in serum electrolytes.

Author: MilesDale R, LacySteven A, WadaDavid R, MilweeSteve, YaronYifah, NguyenLinh T

Cabozantinib for MTC
QTc interval prolongation

This study evaluated factors impacting QTc interval in a phase 3 trial of cabozantinib in progressive, metastatic, medullary thyroid cancer (MTC). Cabozantinib treatment prolongs the ∆∆QTcF interval by 10-15 ms. Decreased serum calcium and potassium could explain the majority of cabozantinib treatment-associated QTcS prolongation observed in this study.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

13.

Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib.

Author: ZuoRena C, ApoloAndrea B, DiGiovannaJohn J, ParnesHoward L, KeenCorrine M, NandaSwati, DahutWilliam L, CowenEdward W

Cancer treatment
Skin reactions

Cabozantinib S-malate is a tyrosine kinase inhibitor with potential efficacy in various cancers. Cutaneous reactions are a common adverse effect, presenting a therapeutic challenge in maximizing the efficacy of targeted cancer therapy.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, N.I.H., IntramuralFunding provided by the NIH for research projects within the NIH.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

15.

Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort.

Author: BaschEthan, AutioKaren A, SmithMatthew R, BennettAntonia V, WeitzmanAaron L, ScheffoldChristian, SweeneyChristopher, RathkopfDana E, SmithDavid C, GeorgeDaniel J, HiganoCelestia S, HarzstarkAndrea L, SartorA Oliver, GordonMichael S, VogelzangNicholas J, de BonoJohann S, HaasNaomi B, CornPaul G, SchimmollerFrauke, ScherHoward I

Improved functioning
Pain palliation
Reduced narcotics

Cabozantinib demonstrated clinically meaningful pain palliation, reduced or eliminated patients' narcotic use, and improved patient functioning.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.